BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

486 related articles for article (PubMed ID: 33541566)

  • 1. Changing levels of sex hormones and calcitonin gene-related peptide (CGRP) during a woman's life: Implications for the efficacy and safety of novel antimigraine medications.
    de Vries Lentsch S; Rubio-Beltrán E; MaassenVanDenBrink A
    Maturitas; 2021 Mar; 145():73-77. PubMed ID: 33541566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CGRP and Migraine: The Role of Blocking Calcitonin Gene-Related Peptide Ligand and Receptor in the Management of Migraine.
    Maasumi K; Michael RL; Rapoport AM
    Drugs; 2018 Jun; 78(9):913-928. PubMed ID: 29869205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
    Favoni V; Giani L; Al-Hassany L; Asioli GM; Butera C; de Boer I; Guglielmetti M; Koniari C; Mavridis T; Vaikjärv M; Verhagen I; Verzina A; Zick B; Martelletti P; Sacco S;
    J Headache Pain; 2019 Mar; 20(1):27. PubMed ID: 30866804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Calcitonin Gene-Related Peptide (CGRP) Antagonists and Their Use in Migraines.
    Henson B; Hollingsworth H; Nevois E; Herndon C
    J Pain Palliat Care Pharmacother; 2020 Mar; 34(1):22-31. PubMed ID: 31763951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CGRP as the target of new migraine therapies - successful translation from bench to clinic.
    Edvinsson L; Haanes KA; Warfvinge K; Krause DN
    Nat Rev Neurol; 2018 Jun; 14(6):338-350. PubMed ID: 29691490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel migraine treatment with CGRP-related monoclonal antibodies].
    Shibata M
    Rinsho Shinkeigaku; 2020 Oct; 60(10):668-676. PubMed ID: 32893246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs.
    Villalón CM; Olesen J
    Pharmacol Ther; 2009 Dec; 124(3):309-23. PubMed ID: 19796656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine.
    Yuan H; White CS; Silberstein SD
    Clin Pharmacol Ther; 2019 May; 105(5):1121-1129. PubMed ID: 30648737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis.
    Tringali G; Navarra P
    Peptides; 2019 Jun; 116():16-21. PubMed ID: 31018157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcitonin Gene-Related Peptide Modulators - The History and Renaissance of a New Migraine Drug Class.
    Hargreaves R; Olesen J
    Headache; 2019 Jun; 59(6):951-970. PubMed ID: 31020659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Calcitonin gene-related peptide (CGRP): a new target for migraine.
    Russo AF
    Annu Rev Pharmacol Toxicol; 2015; 55():533-52. PubMed ID: 25340934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erenumab in the treatment of migraine.
    Jain S; Yuan H; Spare N; Silberstein SD
    Pain Manag; 2018 Nov; 8(6):415-426. PubMed ID: 30235976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CGRP and migraine: from bench to bedside.
    Edvinsson L
    Rev Neurol (Paris); 2021 Sep; 177(7):785-790. PubMed ID: 34275653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atogepant for migraine.
    Bedrin K; Ailani J
    Drugs Today (Barc); 2022 Aug; 58(8):399-405. PubMed ID: 35983926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting calcitonin gene-related peptide: a new era in migraine therapy.
    Charles A; Pozo-Rosich P
    Lancet; 2019 Nov; 394(10210):1765-1774. PubMed ID: 31668411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.
    Edvinsson L
    J Intern Med; 2022 Oct; 292(4):575-586. PubMed ID: 35532284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic Considerations for the Use of Monoclonal Antibodies in Migraine.
    Levin M; Silberstein SD; Gilbert R; Lucas S; Munsie L; Garrelts A; Kennedy K; Everman N; Pearlman E
    Headache; 2018 Nov; 58(10):1689-1696. PubMed ID: 30426478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blocking CGRP in migraine patients - a review of pros and cons.
    Deen M; Correnti E; Kamm K; Kelderman T; Papetti L; Rubio-Beltrán E; Vigneri S; Edvinsson L; Maassen Van Den Brink A;
    J Headache Pain; 2017 Sep; 18(1):96. PubMed ID: 28948500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development.
    Bigal ME; Walter S; Rapoport AM
    Headache; 2013 Sep; 53(8):1230-44. PubMed ID: 23848260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CGRP inhibitors for migraine prophylaxis: a safety review.
    Rivera-Mancilla E; Villalón CM; MaassenVanDenBrink A
    Expert Opin Drug Saf; 2020 Oct; 19(10):1237-1250. PubMed ID: 32811190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.